Propanc Biopharma Inc., of Melbourne, Australia, disclosed the execution of a research collaboration agreement with the University of Jaén in Spain, for the provision of research services and scientific technical advice for the company's POP1 drug discovery program. The goal for the program is to synthesize and develop a backup clinical compound to the company's lead product candidate, PRP.